Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Curr Oncol. 2022 May 26;29(6):3860-3869. doi: 10.3390/curroncol29060308.
Self-collection may provide an opportunity for innovation within population-based human papillomavirus (HPV) cervical cancer screening programs by providing an alternative form of engagement for all individuals. The primary objective was to determine willingness to self-collect a vaginal sample for primary HPV screening and factors that impact willingness in individuals who participated in the Human Papillomavirus For Cervical Cancer (HPV FOCAL) screening trial, a large randomized controlled cervical screening trial. A cross-sectional online survey was distributed between 2017 and 2018 to 13,176 eligible participants exiting the FOCAL trial. Bivariate and multivariable logistic regression assessed factors that influence willingness to self-collect on 4945 respondents. Overall, 52.1% of respondents indicated willingness to self-collect an HPV sample. In multivariable analysis, the odds of willingness to self-collect were significantly higher in participants who agreed that screening with an HPV test instead of a Pap test was acceptable to them (odds ratio (OR): 1.45 (95% confidence interval (CI): 1.15, 1.82), those who indicated that collecting their own HPV sample was acceptable to them (p < 0.001), and those with higher educational ascertainment (OR: 1.31, 95% CI: 1.12, 1.54). The findings offer insight into the intentions to self-collect in those already engaged in screening, and can inform cervical cancer screening programs interested in offering alternative approaches to HPV-based screening.
自我采样可能为基于人群的人乳头瘤病毒 (HPV) 宫颈癌筛查计划提供创新机会,为所有个体提供另一种参与方式。主要目的是确定参与人乳头瘤病毒用于宫颈癌 (HPV FOCAL) 筛查试验的个体对自我采集阴道样本进行 HPV 初筛的意愿,以及影响其意愿的因素,该试验是一项大型随机对照宫颈癌筛查试验。2017 年至 2018 年期间,对 13176 名符合条件的 FOCAL 试验退出者进行了横断面在线调查。二变量和多变量逻辑回归评估了 4945 名受访者中影响自我采集意愿的因素。总体而言,52.1%的受访者表示愿意自我采集 HPV 样本。在多变量分析中,与同意 HPV 检测代替巴氏涂片检测对他们来说可接受的参与者相比,愿意自我采集 HPV 样本的可能性显著更高(优势比 (OR):1.45 (95%置信区间 (CI):1.15, 1.82))、那些表示自我采集 HPV 样本可接受的参与者(p < 0.001)以及接受更高教育程度调查的参与者(OR:1.31,95% CI:1.12,1.54)。这些发现为已经参与筛查的个体提供了自我采集的意图的见解,并为有兴趣提供 HPV 筛查替代方法的宫颈癌筛查计划提供了信息。